CelLBxHealth enters service agreement with AstraZeneca, shares pop.

CelLBxHealth said on Friday that it had entered into a master services agreement with AstraZeneca, establishing the company as a qualified service provider to the global pharmaceutical group.

CellbXhealth
29 May 2026 14:20:45

Source: Sharecast

The AIM-traded company, formerly known as Angle and which specialises in circulating tumour cell, or CTC, solutions for research, drug development and clinical oncology, said the agreement would allow it to support AstraZeneca’s drug discovery and development work through CTC-powered analytics of clinical trial samples.

It said the work would use its Parsortix platform, which is designed to analyse circulating tumour cells.

Chief executive officer Peter Collins said the agreement would give AstraZeneca access to CelLBxHealth’s capabilities across its development pipeline.

“We are delighted to enter into this master services agreement which enables AstraZeneca to access our capabilities across their development pipeline,” Collins said.

“We look forward to delivering strong and productive outcomes through this framework.”

At 1354 BST, shares in CelLBxHealth were up 28.58% at 2.22p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.